TY - JOUR
T1 - Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas
AU - Braunstein, Zachary
AU - Waller, Allyson
AU - Dotson, Emily
AU - McLaughlin, Eric
AU - Hanel, Walter
AU - Reneau, John
AU - Addison, Daniel
AU - Porcu, Pierluigi
AU - Brammer, Jonathan Edward
N1 - Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2024
Y1 - 2024
N2 - Aggressive T-cell lymphomas (TCL) account for 10–15% of non-Hodgkin lymphomas (NHL) with weaker responses and shorter durations to chemotherapy than other types of NHL. Current therapies for patients with relapsed/refractory Cutaneous T-cell lymphoma (CTCL) have limited efficacy, and short durations of response. Gemcitabine and liposomal doxorubicin have shown single-agent activity in TCL and combined have activity in relapsed B-cell lymphomas. We evaluated outcomes of 18 patients with relapsed/refractory aggressive TCL (13 CTCL, 5 PTCL) treated with a gemcitabine plus liposomal doxorubicin (GemDox) combination and evaluated outcomes with a specific focus on CTCL patients. Significant responses were observed in CTCL patients with an overall response rate of over 80%. In all patients, objective responses were seen in eight patients (50%), with six patients (5 CTCL) able to proceed to allogeneic stem cell transplant. Given limited treatment options for r/r CTCL, GemDox should be considered a therapeutic option in relapsed/refractory CTCL.
AB - Aggressive T-cell lymphomas (TCL) account for 10–15% of non-Hodgkin lymphomas (NHL) with weaker responses and shorter durations to chemotherapy than other types of NHL. Current therapies for patients with relapsed/refractory Cutaneous T-cell lymphoma (CTCL) have limited efficacy, and short durations of response. Gemcitabine and liposomal doxorubicin have shown single-agent activity in TCL and combined have activity in relapsed B-cell lymphomas. We evaluated outcomes of 18 patients with relapsed/refractory aggressive TCL (13 CTCL, 5 PTCL) treated with a gemcitabine plus liposomal doxorubicin (GemDox) combination and evaluated outcomes with a specific focus on CTCL patients. Significant responses were observed in CTCL patients with an overall response rate of over 80%. In all patients, objective responses were seen in eight patients (50%), with six patients (5 CTCL) able to proceed to allogeneic stem cell transplant. Given limited treatment options for r/r CTCL, GemDox should be considered a therapeutic option in relapsed/refractory CTCL.
KW - Chemotherapeutic approaches
KW - lymphoma and Hodgkin disease
KW - pharmacotherapeutics
UR - http://www.scopus.com/inward/record.url?scp=85179722637&partnerID=8YFLogxK
U2 - 10.1080/10428194.2023.2287965
DO - 10.1080/10428194.2023.2287965
M3 - Article
C2 - 38093530
AN - SCOPUS:85179722637
SN - 1042-8194
VL - 65
SP - 301
EP - 311
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 3
ER -